Titre :

Are unknown co-medications, over-the-counter and off-label drug use still problems among people living with HIV? Results from a transversal survey in 23 centres in France.

Auteur(s) :

Tetart, Macha [Auteur]
Centre Hospitalier de Tourcoing
Passecountrin, Priscila [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Lesourd, Anaïs [Auteur]
Service des maladies infectieuses et tropicales [Rouen]
Sanderink, Diane [Auteur]
Centre Hospitalier Universitaire d'Angers [CHU Angers]
Le Moal, Gwenaël [Auteur]
Centre hospitalier universitaire de Poitiers = Poitiers University Hospital [CHU de Poitiers [La Milétrie]]
Surgers, Laure [Auteur]
CHU Saint-Antoine [AP-HP]
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
Beraud, Guillaume [Auteur]
CHU Rouen
Katlama, Christine [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Robineau, Olivier [Auteur]
CHU Saint-Antoine [AP-HP]
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
Centre Hospitalier de Tourcoing
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Parienti, Jean-Jacques [Auteur]
CHU Caen

Titre de la revue :

Journal of Antimicrobial Chemotherapy

Nom court de la revue :

J Antimicrob Chemother

Date de publication :

2023-09-29

ISSN :

1460-2091

Résumé en anglais : [en]

Introduction Polypharmacy can lead to drug–drug interactions (DDIs), especially with ART. The burden of co-medications, including over-the-counter (OTC) drugs and self-medications, could be underestimated. We aimed to ...
Lire la suite >Introduction Polypharmacy can lead to drug–drug interactions (DDIs), especially with ART. The burden of co-medications, including over-the-counter (OTC) drugs and self-medications, could be underestimated. We aimed to investigate the proportion of people living with HIV (PLHIV) with declared and undeclared co-medications, as well as their potential burden. Methods We conducted a national, multicentre, 1 week cross-sectional study between 10 December and 16 December 2019 in 23 French hospitals amongst consecutive adult PLHIV presenting for a routine outpatient visit. A standardized questionnaire filled in by the physicians assessed all medications and other active chemical substances taken by the PLHIV. Results Overall we enrolled 496 participants from 23 centres. Median age was 50.6 years; ART regimens included an integrase inhibitor in 61% (n = 302), an NNRTI in 34% (n = 169) and a PI in 14% (n = 70) of the cases. Co-medications involved 392 (79%) PLHIV, among which 85 (17%) received polypharmacy (≥5 medications). Previously unknown co-medications or other active substances were found for 32% (n = 159) of the participants. Corticosteroids (9%, n = 46) and proton pump inhibitors (10%, n = 50) were frequently administered. These co-medications did not differ according to age range. Illegal drug use was declared by 11% (n = 54) and OTC drugs by 23% (n = 113) of PLHIV. Potential DDIs were discovered for 11% (n = 53), leading to treatment modifications in 47% (25/53) of cases. Conclusions Potential DDIs that lead to therapeutic modifications remain significant whatever the age of PLHIV. More devoted time to identify co-medications and OTC treatment is needed in all PLHIV.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Date de dépôt :

2024-02-21T22:10:29Z
2024-04-10T14:07:10Z